A clinical trial of phases 2 and 3 including NASH patients, with and without T2DM, showed that OCA treatment for 6 weeks in patients with NASH and T2DM ameliorated insulin sensitivity as well as some parameters of fibrosis and inflammation in a dose-dependent way [32]. This evidence concerns the gene INS and type 2 diabetes mellitus.